Quick Answer
Prelude Therapeutics Inc reported Operating Income of -$104.57 million for fiscal year 2025.
Prelude Therapeutics Inc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$104.57M | +25.2% |
| 2024 | -$139.71M | -5.6% |
| 2023 | -$132.28M | -7.1% |
| 2022 | -$123.54M | -8.6% |
| 2021 | -$113.73M | -93.5% |
| 2020 | -$58.76M | -109.1% |
| 2019 | -$28.11M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$20.42M | +40.6% | +36.6% |
| June 30, 2025 | -$32.19M | +13.4% | +7.0% |
| March 31, 2025 | -$34.61M | -0.8% | -0.7% |
| September 30, 2024 | -$34.38M | -3.0% | +7.5% |
| June 30, 2024 | -$37.16M | -14.7% | -8.2% |
| March 31, 2024 | -$34.34M | -18.0% | -2.9% |
| September 30, 2023 | -$33.38M | -9.8% | -3.0% |
| June 30, 2023 | -$32.40M | -10.0% | -11.3% |
- Prelude Therapeutics Inc showed an increase of +25.2% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Prelude Therapeutics Inc’s operating income has declined by 272.0% (from -$28.11 million to -$104.57 million).
- The most recent figure is from Prelude Therapeutics Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: